Auris Medical (EARS) Posts Quarterly Earnings Results

Auris Medical (NASDAQ:EARS) issued its earnings results on Thursday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.03), MarketWatch Earnings reports.

Shares of EARS traded down $0.02 during mid-day trading on Friday, hitting $0.60. The stock had a trading volume of 2,200 shares, compared to its average volume of 6,020,284. The firm has a market cap of $4.08 million, a PE ratio of -0.10 and a beta of -1.09. Auris Medical has a 52 week low of $0.23 and a 52 week high of $9.50.

A hedge fund recently bought a new stake in Auris Medical stock. Bellevue Group AG bought a new stake in Auris Medical Holding AG (NASDAQ:EARS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 193,125 shares of the biotechnology company’s stock, valued at approximately $151,000. Bellevue Group AG owned 3.16% of Auris Medical at the end of the most recent reporting period. Institutional investors own 17.96% of the company’s stock.

EARS has been the topic of several research reports. Eurobank EFG initiated coverage on Auris Medical in a research note on Monday, October 8th. They issued a “buy” rating and a $2.50 target price on the stock. ValuEngine upgraded Auris Medical from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.

TRADEMARK VIOLATION WARNING: “Auris Medical (EARS) Posts Quarterly Earnings Results” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at

About Auris Medical

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Further Reading: Momentum Indicator: Relative Strength Index

Earnings History for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.

Leave a Reply